Telmisartan capsule and preparation method thereof

A kind of technology of telmisartan and capsule

Active Publication Date: 2014-11-12
HENAN RUNHONG PHARMA
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The object of the present invention is to provide a kind of telmisartan capsule, solve the problem that existing telmisartan dosage form is not stable, dissolution rate is low, and bioavailability is not high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Telmisartan capsule and preparation method thereof
  • Telmisartan capsule and preparation method thereof
  • Telmisartan capsule and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] The telmisartan capsule of the present embodiment, every 1000 described telmisartan capsules comprise following components: telmisartan 40g, lactose 210g, sodium hydroxide 3.2g, meglumine 6.0g, polysaccharide Ethanol solution of Vitone K30 25ml.

[0030] The capsules are hard capsules.

[0031] The preparation method of the telmisartan capsule of the present embodiment comprises the following steps:

[0032] 1) Dissolve 3.2 g of sodium hydroxide and 6.0 g of meglumine in a small amount of 50% ethanol aqueous solution, add telmisartan, mix and grind to obtain mixture A;

[0033] 2) Add 210g of lactose to mixture A, mix and dry at 50°C for 60 minutes, then pulverize and pass through a 40-mesh sieve to obtain a mixed fine powder;

[0034] 3) Add 25ml of ethanol solution of povidone K30 with a mass concentration of 5% to the mixed fine powder obtained in step 2) to make a soft material, and pass through a 20-mesh sieve to make wet granules;

[0035] 4) After drying the w...

Embodiment 2

[0038] The telmisartan capsule of the present embodiment, every 1000 described telmisartan capsules comprise following components: telmisartan 40g, lactose 210g, sodium hydroxide 3.2g, meglumine 6.0g, polysaccharide Ethanol solution of Vitone K30 25ml.

[0039] The capsules are hard capsules.

[0040] The preparation method of the telmisartan capsule of the present embodiment comprises the following steps:

[0041] 1) Dissolve 3.2 g of sodium hydroxide and 6.0 g of meglumine in a small amount of 50% ethanol aqueous solution, add telmisartan, mix and grind to obtain mixture A;

[0042] 2) Add 210g of lactose to mixture A, mix and dry at 60°C for 30 minutes, then pulverize and pass through a 40-mesh sieve to obtain a mixed fine powder;

[0043] 3) Add 25ml of ethanol solution of povidone K30 with a mass concentration of 5% to the mixed fine powder obtained in step 2) to make a soft material, and pass through a 20-mesh sieve to make wet granules;

[0044] 4) After drying the w...

Embodiment 3

[0047] The telmisartan capsule of the present embodiment, every 1000 described telmisartan capsules comprise following components: telmisartan 40g, lactose 210g, sodium hydroxide 3.2g, meglumine 6.0g, polysaccharide Ethanol solution of Vitone K30 25ml.

[0048] The capsules are hard capsules.

[0049] The preparation method of the telmisartan capsule of the present embodiment comprises the following steps:

[0050] 1) Dissolve 3.2 g of sodium hydroxide and 6.0 g of meglumine in a small amount of 50% ethanol aqueous solution, add telmisartan, mix and grind to obtain mixture A;

[0051] 2) Add 210g of lactose to mixture A, mix and dry at 55°C for 45 minutes, then pulverize and pass through a 40-mesh sieve to obtain a mixed fine powder;

[0052] 3) Add 25ml of ethanol solution of povidone K30 with a mass concentration of 5% to the mixed fine powder obtained in step 2) to make a soft material, and pass through a 20-mesh sieve to make wet granules;

[0053] 4) After drying the w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a telmisartan capsule and a preparation method thereof. Every 1000 telmisartan capsules comprises the following components: 40g of telmisartan, 210g of lactose, 3.2g of sodium hydroxide, 6.0g of meglumine, 25ml of an ethanol solution of povidone K30. The telmisartan capsule provided by the invention adopts telmisartan as the main drug, and selects sodium hydroxide, meglumine, and the ethanol solution of povidone K30 as auxiliary materials, so that the dissolution rate of the telmisartan capsule is greatly improved, and accordingly the bioavailability of the capsule is enhanced. With good initial stability and long-term stability, as well as good oral absorption, the telmisartan capsule has remarkable curative effect on hypertension.

Description

technical field [0001] The invention belongs to the technical field of medicine, in particular to a telmisartan capsule, and also relates to a preparation method of the telmisartan capsule. Background technique [0002] In recent years, hypertension has become one of the main killers that endanger human health. Drugs for the treatment of hypertension mainly include thiazide diuretics, β-blockers, calcium antagonists, angiotensin-converting enzyme inhibitors (ACEI), α-adrenoceptor blockers and angiotensin II receptor antagonists (ATl receptor antagonist). Among them, angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor antagonists (AT1 receptor antagonists) are the two most important antihypertensive drugs. Telmisartan is one of the latest and greatest additions to the sartan class. [0003] Telmisartan, also known as BIBR277, was developed by Boehringer Ingelheim in Germany and was approved by the US Food and Drug Administration on November...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/48A61K31/4184A61K47/02A61K47/26A61K47/32A61P9/12
Inventor 靳勇
Owner HENAN RUNHONG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap